Form 4: Eagle Pharmaceuticals Executive Scott Tarriff Reports Stock Transactions

Scott Tarriff, an executive at Eagle Pharmaceuticals, reported the acquisition and disposition of company stock related to vesting performance stock units and tax liabilities.

Summary

• On February 27, 2024, Scott Tarriff acquired 12,950 shares of Eagle Pharmaceuticals common stock upon the vesting of performance stock units (PSUs) granted on February 2, 2021.
• On the same day, 3,154 shares were disposed of to cover tax liabilities related to the PSU vesting at a price of $6.44 per share.
• Following these transactions, Tarriff directly owns 462,740 shares of common stock.
• Additionally, 992,623 shares are held indirectly by the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016, for the benefit of Tarriff's spouse and children, over which Tarriff disclaims beneficial ownership except to the extent of any pecuniary interest.
• A transfer of 88,181 shares of Common Stock occurred pursuant to a Rule 16a-12 transaction.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and tax obligations. There's no indication of significant positive or negative news.

Positives

• The vesting of performance stock units suggests that performance goals were met, which could be viewed positively.

Negatives

• The sale of shares to cover tax liabilities could be seen as a minor negative, although it's a common practice.

Risks

• The document does not explicitly mention any risks.

Industry Context

Form 4 filings are standard disclosures required by the SEC for insiders of publicly traded companies, providing transparency into their transactions in the company's stock. This filing indicates routine transactions related to executive compensation.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies and their insiders, ensuring transparency and compliance with SEC regulations.
• Similar filings are common among executives at comparable pharmaceutical companies like Teva Pharmaceuticals, Mylan (now Viatris), and Amgen, reflecting stock-based compensation and related transactions.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are routine and related to executive compensation.

Key Dates

Keywords

Eagle Pharmaceuticals, Scott Tarriff, Form 4, Beneficial Ownership, Stock Transaction, PSU, Vesting, Tax Liability